Table 3 The modified ANOVA-type statistic based on the group effect for 14 QLQ-C30 scales/items.

From: Effects of rice bran arabinoxylan compound on quality of life of cancer patients during active treatment: a randomised placebo-controlled pilot trial

Scale/item

mATS

Df1

Df2

p-value

Physical functioning (PF2)

2.36

1

18.35

0.141

Role functioning (RF2)

22.21

1

19.85

< 0.001*

Emotional functioning (EF)

0.09

1

18.82

0.767

Cognitive functioning (CF)

4.17

1

19.49

0.054 +

Social functioning (SF)

4.99

1

19.41

0.037*

Fatigue (FA)

4.59

1

19.17

0.045*

Nausea and vomiting (NV)

< 0.01

1

18.16

0.967

Pain (PA)

4.43

1

19.42

0.048*

Dyspnoea (DY)

4.53

1

18.49

0.047*

Insomnia (SL)

0.45

1

19.96

0.508

Appetite loss (AP)

4.64

1

20.00

0.044*

Constipation (CO)

0.06

1

19.35

0.804

Diarrhoea (DI)

0.80

1

13.91

0.387

Financial difficulties (FI)

4.25

1

13.71

0.058 +

  1. Significant values are in bold.
  2. *The statistically significant difference between groups (RBAC vs. Placebo) was based on the modified ANOVA-type statistic for the whole-plot factors (mATS) with p ≤ 0.05. + Marginal significance p ≈ 0.05. Df = Degree of freedom; RBAC = rice bran arabinoxylan compound.
Back to article page